Haisco Partners with AbbVie in $745 Million Pain Therapy Licensing Deal
核心洞察
Haisco Pharmaceutical has granted AbbVie exclusive global rights to develop and commercialize multiple novel pain compounds, excluding China, Hong Kong, and Macau.
The licensing agreement includes an upfront payment of $30 million and potential milestone payments totaling up to $715 million, plus tiered royalties on future sales.
The compounds are currently in various development stages ranging from preclinical to Phase 1 clinical trials in China.
Chinese pharmaceutical company Haisco Pharmaceutical Group Co., Ltd. has entered into a significant exclusive licensing agreement with global biopharmaceutical giant AbbVie, granting the latter worldwide rights to develop, manufacture, and commercialize novel pain medicines. The deal, announced on April 10, 2026, excludes mainland China, Hong Kong, and Macau from AbbVie's territorial rights.
Financial Terms and Structure
Under the agreement, Haisco will receive an immediate upfront payment of $30 million, with the potential to earn up to $715 million in aggregate development, regulatory, and commercial milestone payments. The company is also eligible for tiered royalties on future net sales, bringing the total deal value to potentially $745 million.
Compound Portfolio and Development Status
The licensing program encompasses multiple compounds specifically designed to address pain-related indications. These therapeutic candidates are currently at various stages of development within China, ranging from preclinical research to Phase 1 clinical trials. The compounds represent part of Haisco's broader pain management portfolio within its diversified research and development pipeline.
Strategic Rationale and Leadership Perspective
"This collaboration is highly aligned with our international development strategy and is expected to generate sustainable value and long-term returns," said Dr. Pangke Yan, chief executive officer of Haisco. "By partnering with a global biopharmaceutical leader such as AbbVie, Haisco aims to accelerate the global development of innovative pain therapies and deliver high-quality treatment options to patients worldwide."
The partnership strategically positions Haisco to leverage AbbVie's established development and commercialization infrastructure, particularly benefiting from the company's recognized expertise in neuroscience therapeutics.
Company Background and R&D Capabilities
Haisco operates as a benchmark enterprise in China's innovative pharmaceutical sector, following a core strategy of "innovation-driven growth and global expansion." The company maintains a diversified R&D pipeline that includes small-molecule innovative drugs, biologics, and high-end generics across multiple therapeutic areas including pain management, oncology, respiratory diseases, autoimmune disorders, metabolic diseases, and central nervous system disorders.
The company is actively advancing more than 50 R&D programs, with over 10 having progressed to pivotal clinical stages. Haisco has demonstrated substantial commitment to research and development, investing more than 15% of revenue in R&D activities for each of the past three years. The company's research infrastructure includes major R&D centers in Chengdu, Shanghai, and Silicon Valley, supported by a research team with extensive global experience.
Global Expansion Strategy
Haisco initiated its international expansion strategy in 2015 and has since pursued global market entry through various mechanisms, including out-licensing transactions, co-development partnerships, and overseas mergers and acquisitions. This AbbVie collaboration represents a continuation of the company's established approach to international partnerships and market expansion.